ASX-LISTED Mayne Pharma Group Limited has signed an exclusive licence agreement with US-based TherapeuticsMD for three branded women's health products and a portfolio of prenatal vitamins in the USA.
The US$140 million deal "significantly enhances Mayne Pharma's position in the US women's health market," the company said.
The additions include Annovera (segesterone acetate/ethinyl estradiol), Imvexxy (estradiol); and Bijuva (estradiol and progesterone) capsules which are "the first and only FDA-approved bio-identical hormone therapy in a single, oral daily capsule for the treatment of hot flushes" experienced during menopause.
Mayne Pharma said it would also exclusively licence the BocaGreen MD and vitaMedMD lines of prenatal vitamins, and expand its existing womens' health sales team and add additional sales representatives into new territories not already covered for its Nexstellis oral contraceptive product.
The above article was sent to subscribers in Pharmacy Daily's issue from 12 Dec 22
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 12 Dec 22
